JP2022502052A5 - - Google Patents
Info
- Publication number
- JP2022502052A5 JP2022502052A5 JP2021517309A JP2021517309A JP2022502052A5 JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5 JP 2021517309 A JP2021517309 A JP 2021517309A JP 2021517309 A JP2021517309 A JP 2021517309A JP 2022502052 A5 JP2022502052 A5 JP 2022502052A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- hla
- seq
- molecule
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024169203A JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737666P | 2018-09-27 | 2018-09-27 | |
| US62/737,666 | 2018-09-27 | ||
| PCT/US2019/053158 WO2020069133A1 (en) | 2018-09-27 | 2019-09-26 | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169203A Division JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502052A JP2022502052A (ja) | 2022-01-11 |
| JP2022502052A5 true JP2022502052A5 (https=) | 2022-10-04 |
| JPWO2020069133A5 JPWO2020069133A5 (https=) | 2022-10-04 |
| JP7588068B2 JP7588068B2 (ja) | 2024-11-21 |
Family
ID=68296637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517309A Active JP7588068B2 (ja) | 2018-09-27 | 2019-09-26 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
| JP2024169203A Pending JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169203A Pending JP2024177227A (ja) | 2018-09-27 | 2024-09-27 | 抗ｈｌａ－ｇ抗体、抗ｈｌａ－ｇ抗体を含む組成物、および抗ｈｌａ－ｇ抗体を使用する方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US11208487B2 (https=) |
| EP (1) | EP3856780A1 (https=) |
| JP (2) | JP7588068B2 (https=) |
| KR (1) | KR102867868B1 (https=) |
| CN (2) | CN113166243B (https=) |
| AR (2) | AR116526A1 (https=) |
| AU (1) | AU2019346598B2 (https=) |
| BR (1) | BR112021005868A2 (https=) |
| CA (1) | CA3114407A1 (https=) |
| CL (2) | CL2021000761A1 (https=) |
| CO (1) | CO2021004719A2 (https=) |
| CR (1) | CR20210197A (https=) |
| DO (1) | DOP2021000049A (https=) |
| EA (1) | EA202190609A1 (https=) |
| EC (1) | ECSP21026339A (https=) |
| IL (1) | IL281778A (https=) |
| MX (1) | MX2021003555A (https=) |
| MY (1) | MY204959A (https=) |
| NZ (1) | NZ774376A (https=) |
| PE (1) | PE20211767A1 (https=) |
| PH (1) | PH12021550690A1 (https=) |
| SG (1) | SG11202103104RA (https=) |
| TW (2) | TW202438522A (https=) |
| UA (1) | UA129052C2 (https=) |
| UY (1) | UY38391A (https=) |
| WO (1) | WO2020069133A1 (https=) |
| ZA (2) | ZA202102034B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428604A (zh) | 2018-07-09 | 2024-07-16 | 美商戊瑞治療有限公司 | 結合至ilt4的抗體 |
| IL293670A (en) | 2019-12-09 | 2022-08-01 | Twist Bioscience Corp | Variable nucleic acid libraries for adenosine receptors |
| IL298867A (en) * | 2020-06-11 | 2023-02-01 | Tizona Therapeutics | Bispecific immune cell engagers with binding specificity for hla-g and another antigen |
| WO2022159620A1 (en) * | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| US12012454B2 (en) * | 2021-03-24 | 2024-06-18 | China Medical University Hospital | Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| US11795227B2 (en) * | 2021-03-24 | 2023-10-24 | Shine-On Biomedical Co., Ltd. | Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| CN115925930B (zh) * | 2021-11-04 | 2025-10-31 | 台州恩泽医疗中心(集团) | 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途 |
| WO2023182866A1 (ko) * | 2022-03-25 | 2023-09-28 | 에이치케이이노엔 주식회사 | Hla-g 특이적 항체 및 이의 용도 |
| CN115819583B (zh) * | 2022-03-31 | 2026-03-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
| US20250223363A1 (en) * | 2022-04-08 | 2025-07-10 | Tizona Therapeutics, Inc. | Combination therapy involving anti-hla-g antibodies and anti-egfr antibodies, anti-pd1 or anti-pd-l1 antibodies, and/or anti-cd47 |
| CN119768507A (zh) * | 2022-06-24 | 2025-04-04 | 怡诺安有限公司 | 表达免疫检查点调节剂的免疫细胞及其用途 |
| CN117448412A (zh) * | 2022-07-26 | 2024-01-26 | 中山大学孙逸仙纪念医院 | CD158d分子、其中和抗体，及应用 |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN119569891B (zh) * | 2023-09-06 | 2025-09-05 | 上海恩凯细胞技术有限公司 | 用于癌症治疗的靶向非经典hla分子的嵌合抗原受体的应用 |
| GB202319122D0 (en) * | 2023-12-14 | 2024-01-31 | Kbio Holdings Ltd | Antibody |
| WO2025165879A1 (en) | 2024-01-29 | 2025-08-07 | Tizona Therapeutics, Inc. | Methods of using anti-hla-g antibodies |
| WO2025245256A1 (en) | 2024-05-22 | 2025-11-27 | Tizona Therapeutics, Inc. | Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| EP0819171A1 (en) | 1995-04-07 | 1998-01-21 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| ES2224603T3 (es) | 1998-02-20 | 2005-03-01 | Commissariat A L'energie Atomique | Procedimiento de seleccion de tumores que expresan hla-g sensibles a un tratamiento anticanceroso y sus aplicaciones. |
| CA2425186A1 (en) | 2000-09-15 | 2002-03-21 | University Of Kansas Medical Center | Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g |
| ES2430857T3 (es) | 2000-12-18 | 2013-11-22 | Dyax Corp. | Bibliotecas focalizadas de paquetes genéticos |
| FR2856599A1 (fr) | 2003-06-30 | 2004-12-31 | Commissariat Energie Atomique | Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang. |
| WO2005042693A2 (ja) | 2003-11-04 | 2005-05-12 | The Animal Engineering Research Institute | Ｈｌａ−ｅキメラ分子 |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| CN1312182C (zh) | 2004-10-26 | 2007-04-25 | 四川新创生物科技有限公司 | 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2445935B1 (en) | 2009-06-25 | 2015-07-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof |
| CN101967191A (zh) | 2009-07-28 | 2011-02-09 | 广州天美生物技术有限公司 | Hla-g抗体制备方法及其在医学中的应用 |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| US20140323315A1 (en) | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| US20190119385A1 (en) | 2015-03-27 | 2019-04-25 | University Of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
| PT3294764T (pt) | 2015-05-15 | 2021-02-15 | Hope City | Composições de recetores de antigénios quiméricos |
| NZ748929A (en) * | 2016-06-03 | 2025-11-28 | Invectys | Anti hla-g specific antibodies |
| TW201829463A (zh) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AU2019328677A1 (en) | 2018-08-31 | 2021-04-01 | Invectys SA | Chimeric antigen receptors against multiple HLA-G isoforms |
-
2019
- 2019-09-26 CR CR20210197A patent/CR20210197A/es unknown
- 2019-09-26 NZ NZ774376A patent/NZ774376A/en unknown
- 2019-09-26 JP JP2021517309A patent/JP7588068B2/ja active Active
- 2019-09-26 PE PE2021000412A patent/PE20211767A1/es unknown
- 2019-09-26 AR ARP190102737A patent/AR116526A1/es unknown
- 2019-09-26 EA EA202190609A patent/EA202190609A1/ru unknown
- 2019-09-26 CN CN201980074775.4A patent/CN113166243B/zh active Active
- 2019-09-26 US US16/584,421 patent/US11208487B2/en active Active
- 2019-09-26 MX MX2021003555A patent/MX2021003555A/es unknown
- 2019-09-26 SG SG11202103104RA patent/SG11202103104RA/en unknown
- 2019-09-26 AU AU2019346598A patent/AU2019346598B2/en active Active
- 2019-09-26 US US17/280,755 patent/US20210340259A1/en not_active Abandoned
- 2019-09-26 EP EP19790902.1A patent/EP3856780A1/en active Pending
- 2019-09-26 CA CA3114407A patent/CA3114407A1/en active Pending
- 2019-09-26 UY UY0001038391A patent/UY38391A/es active IP Right Grant
- 2019-09-26 TW TW112149190A patent/TW202438522A/zh unknown
- 2019-09-26 TW TW108134867A patent/TWI828767B/zh active
- 2019-09-26 CN CN202210745729.6A patent/CN115057932B/zh active Active
- 2019-09-26 UA UAA202101599A patent/UA129052C2/uk unknown
- 2019-09-26 KR KR1020217012047A patent/KR102867868B1/ko active Active
- 2019-09-26 BR BR112021005868-0A patent/BR112021005868A2/pt active Search and Examination
- 2019-09-26 WO PCT/US2019/053158 patent/WO2020069133A1/en not_active Ceased
- 2019-09-26 MY MYPI2021001665A patent/MY204959A/en unknown
-
2021
- 2021-03-24 IL IL281778A patent/IL281778A/en unknown
- 2021-03-25 DO DO2021000049A patent/DOP2021000049A/es unknown
- 2021-03-25 CL CL2021000761A patent/CL2021000761A1/es unknown
- 2021-03-25 ZA ZA2021/02034A patent/ZA202102034B/en unknown
- 2021-03-26 PH PH12021550690A patent/PH12021550690A1/en unknown
- 2021-04-15 EC ECSENADI202126339A patent/ECSP21026339A/es unknown
- 2021-04-15 CO CONC2021/0004719A patent/CO2021004719A2/es unknown
- 2021-11-18 US US17/530,072 patent/US12264199B2/en active Active
-
2022
- 2022-02-14 ZA ZA2022/01874A patent/ZA202201874B/en unknown
-
2023
- 2023-07-13 CL CL2023002048A patent/CL2023002048A1/es unknown
- 2023-08-16 AR ARP230102177A patent/AR130233A2/es unknown
-
2024
- 2024-09-27 JP JP2024169203A patent/JP2024177227A/ja active Pending
-
2025
- 2025-02-27 US US19/065,819 patent/US20250353913A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502052A5 (https=) | ||
| JP7844558B2 (ja) | リンパ球における阻害経路の中和 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| JP2020530289A5 (https=) | ||
| JP2018533371A5 (https=) | ||
| RU2022105827A (ru) | Слитые конструкции антител для вовлечения nk-клеток | |
| JP2021521275A5 (https=) | ||
| JPWO2020069133A5 (https=) | ||
| CN114773475A (zh) | Pd-1结合分子和其使用方法 | |
| JP2021501162A5 (https=) | ||
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| US20240262913A1 (en) | Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| JP2023524238A (ja) | 治療用ＳＩＲＰα抗体 | |
| JP2023530083A (ja) | Ｈｌａ－ｇ及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー | |
| WO2023201309A1 (en) | Antibodies that bind pd-l1, pd-l2 and/or cd28 | |
| JP2019537449A5 (https=) | ||
| WO2021092060A1 (en) | Methods of treatment | |
| TW202144398A (zh) | Ｃｄ１３７結合分子及其用途 | |
| WO2025049613A1 (en) | Anti-cd20 x anti-cd28 combination therapies | |
| JPWO2020123664A5 (https=) | ||
| JPWO2022072601A5 (https=) | ||
| JPWO2022097061A5 (https=) | ||
| RU2021107658A (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g |